International Conference on Network Science and Graph Analytics | NetworkScience | GraphAnalytics | Networking | SocialNetwork | BiologicalNetwork

 Computer-Aided Design of Imatinib Derivatives to Overcome Drug Resistance in CML

Chronic Myeloid Leukemia (CML) often develops resistance to imatinib due to mutations in the BCR-ABL kinase domain, limiting treatment efficacy. Computer-aided drug design (CADD) enables the development of imatinib derivatives with enhanced binding affinity and efficacy against resistant mutations. Molecular docking, molecular dynamics simulations, and ADMET analysis aid in optimizing novel derivatives to overcome resistance. By targeting key resistant variants, these computational approaches help identify promising drug candidates with improved potency and selectivity. This strategy accelerates drug discovery, offering potential new therapies for CML patients who no longer respond to first-line treatments like imatinib.

Role of Computer-Aided Drug Design (CADD)

Computer-aided drug design (CADD) has emerged as a powerful tool for developing new therapeutic compounds. By leveraging computational techniques such as molecular docking, molecular dynamics (MD) simulations, and quantitative structure-activity relationship (QSAR) modeling, researchers can design and optimize imatinib derivatives with enhanced potency and selectivity.

1. Molecular Docking:

   • Used to predict the binding affinity of novel imatinib derivatives to both wild-type and mutant BCR-ABL proteins.
   • Helps in identifying molecules with strong interactions and optimal binding conformations.

2. Molecular Dynamics Simulations:

   • Provides insights into the stability and flexibility of drug-protein interactions over time.
   • Simulates physiological conditions to assess how derivatives behave within a cellular environment.

3. ADMET Analysis (Absorption, Distribution, Metabolism, Excretion, and Toxicity):

   • Predicts pharmacokinetic and toxicity profiles to identify promising drug candidates.
   • Ensures derivatives have optimal drug-like properties with minimal side effects.

Designing Imatinib Derivatives

Through virtual screening and molecular modifications, researchers can develop novel imatinib analogs with:

• Improved binding affinity to BCR-ABL, including resistant mutants.
• Increased hydrophobic interactions, hydrogen bonding, and π-π stacking with key residues.
• Structural modifications that prevent steric hindrance, allowing better access to the active site.

Potential Impact

By utilizing CADD approaches, researchers can accelerate the discovery of next-generation TKIs that overcome resistance in CML patients. These derivatives could serve as alternatives for patients who fail imatinib therapy, offering new hope in targeted cancer treatment.

International Research Awards on Network Science and Graph Analytics

Visit Our Website : https://networkscience.researchw.com/

Nominate Now : https://networkscience-conferences.researchw.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Contact us : network@researchw.com

Get Connected Here:
*****************

Instagram: https://www.instagram.com/emileyvaruni/
Tumblr: https://www.tumblr.com/emileyvaruni
Pinterest: https://in.pinterest.com/emileyvaruni/
Blogger: https://emileyvaruni.blogspot.com/
Twitter: https://x.com/emileyvaruni
YouTube: https://www.youtube.com/@emileyvaruni

#sciencefather #researchw  #researchawards #NetworkScience #GraphAnalytics  #ResearchAwards  #InnovationInScience #TechResearch  #DataScience #GraphTheory  #ScientificExcellence  #AIandNetworkScience     #Imatinib, #CML, Chronic Myelogenous Leukemia, #DrugResistance, #CancerResearch, #ComputerAidedDesign, #MolecularModeling, #DrugDesign, #Pharmacology, #Chemoinformatics, #CancerTherapy, #BiomedicalResearch, #DrugDiscovery, #MolecularDocking, #OncologyResearch, #TargetedTherapy